Nanomedicine is the application of nanotechnology to achieve innovation in healthcare. It uses the properties developed by a material at its nanometric scale 10-9 m which often differ in terms of physics, chemistry or biology from the same material at a bigger scale.

Moreover, the nanometric size is also the scale of many biological mechanisms in the human body allowing nanoparticles and nanomaterials to potentially cross natural barriers to access new sites of delivery and to interact with DNA or small proteins at different levels, in blood or within organs, tissues or cells.

Key reasons to become a member:

Meet new partners and end-users
Share your success stories
Benefit from unique advantages
Shape the future of Nanomedicine in europe
Promote and educate

Know more

ETPN strategic inputs

As a major pan-European industry-oriented initiative, the ETPN aims at strengthening Europe’s capabilities and competitiveness in the area of nanomedicine innovation. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe.

We have contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine.

Know more

ETPN support to innovation

Complementary to its strategic inputs as an ETP to shape and support public funding on the most promising areas of Nanomedicine, the ETPN has designed in 2014 unique technical infrastructures regrouped in a central instrument: the Nanomedicine Translation HUB.

These free of charge services support and accelerate the development of the best Nanomedicine projects from innovative design to clinical development.

Know more

Are you on the Nanomedicine map?

The NanoMed Map provides thorough insights into the nanomedicine community by showing all the actors of the ecosystem in Europe and beyond. It was initiated by NanoMed 2020, CSA project under FP7_Health.

See the map



Latest news

European Organ-On-Chip Society launched

Nov 13, 2018

The new European Organ-on-Chip Society (EUROoCS) was officially launched at the third International Organ-on-Chip Symposium, held on 8 and 9 November 2018 at the University of Technology in Eindhoven, the Netherlands. The Society will encourage development and...

Nanobiotix won the Pharma Company of the Year award at CPhIAwards

Oct 10, 2018

Nanobiotix, the late clinical-stage Nanomedicine company and Platinum member of the ETPN has been rewarded during the ceremony 2018 of the CphI Awards on October 9 in Madrid, Spain. Nanobiotix won Pharma Company of the Year Laurent Lévy, CEO of Nanobiotix, won CEO of...